VNDA News & Events

Geron (GERN) announced the appointment of Timothy Williams as executive VP, chief legal officer and corporate secretary. Tim Williams served as senior VP, general counsel and Secretary at Vanda Pharmaceuticals (VNDA) from 2018 until March.

Vanda Pharmaceuticals highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification.The proposal would eliminate the simple statutory requirement that the FDA must review a new drug application within 180 days of filing. In plain terms, this change would extend statutory review timelines rather than shorten them. It would replace the 180-day legal requirement with the longer Prescription Drug User Fee Act and Generic Drug User Fee Amendments performance goals. Under those goals, the FDA takes up to two months simply to decide whether to "file" the application. Only after that does the official review clock begin, resulting in typical total review times of 10 to 12 months from submission to decision. The proposal would also replace the formal evidentiary hearing process required by current law with a weaker, internal streamlined appeal. The FDA has avoided providing the statutorily mandated opportunity for a formal evidentiary hearing on drug non-approvals for over 40 years, until Vanda's successful litigation forced the agency to grant the first such hearing in more than four decades. "The FDA's current practice of exceeding the 180-day statutory timeline by issuing Complete Response Letters and operating under longer PDUFA timelines has already been ruled by federal courts to violate the law," said Mihael Polymeropoulos, CEO. "Instead of complying with the law as written, this proposal asks Congress to change the law so the slower system becomes legal. This is especially concerning because Commissioner Makary said just days ago that the current two-month filing review is too long and should take just days-yet this proposal seeks to codify that very delay into law. At the same time, the FDA seeks to replace the formal hearing process with a streamlined internal appeal, despite the U.S. Court of Appeals for the D.C. Circuit having ruled only months ago that the FDA unlawfully denied Vanda a proper hearing in the HETLIOZ jet-lag case, and after the agency was compelled to grant Vanda the first formal drug approval hearing statutorily required but effectively avoided by the FDA for more than forty years."

Vanda Pharmaceuticals announced the initiation of Thetis, a clinical trial evaluating Nereus - tradipitant - for the prevention of vomiting in patients receiving glucagon-like peptide-1, or GLP-1, receptor agonist therapies. Nereus was recently approved for the prevention of vomiting induced by motion. GLP-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity. However, gastrointestinal side effects, particularly nausea and vomiting, remain a significant challenge for many patients and are a leading cause of treatment discontinuation or dose reduction. The Thetis study will evaluate the efficacy and safety of oral tradipitant in patients initiated at a high dose of a GLP-1 receptor agonist. The primary endpoint is the proportion of patients free from vomiting episodes during the treatment period. The phase 2 study met its primary endpoint, with only 29.3% of tradipitant-treated participants experiencing vomiting compared to 58.6% on placebo, representing a 50% relative reduction. Vanda expects topline results from the Thetis study by Q4. Following completion of the Thetis study, additional study data may be required prior to approval of a NDA.